SanBio Company (4592) Q1 2027 earnings summary

Executive summary

• Advanced regulatory progress for regenerative medicine in Japan and the U.S., with AKUUGO® receiving NHI price listing and commercial launch in Japan in May 2026.

• Continued R&D focus on SB623 for central nervous system diseases, with Phase 3 trial preparations in the U.S. and ischemic stroke program discussions in Japan.

• Operating loss narrowed to ¥953 million from ¥1,007 million year-over-year; net loss attributable to owners of parent improved to ¥836 million from ¥1,531 million.

Financial highlights

• Operating revenue for the quarter was ¥680 million, with R&D expenses at ¥680 million.

• Operating loss was ¥953 million, ordinary loss ¥779 million, and net loss attributable to owners of parent ¥836 million, all improved from the prior year.

• Foreign exchange gains of ¥177 million recorded as non-operating income.

• Comprehensive income was negative ¥972 million, compared to negative ¥880 million year-over-year.

Outlook and guidance

• No revisions to the previously announced financial results forecast for the first half and full year.

• Full-year forecast projects operating loss of ¥5,229 million and net loss per share of ¥65.77.